구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Single - cell cloning |
Overview Company | Celerion |
Overview Modality | CGT |
Overview Target | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Indication | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung Cancer.. The MET receptor tyrosine kinase is mutated or amplified in ~6% of non-small cell lung cancer (NSCLC) and overexpressed in ~80% of all NSCLC cases. A theranostic agent that can both see and treat MET-altered NSCLC has never been described before in the literature. Here, we report a shark-derived single… |
Clinical Safety signal | A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung Cancer.. The MET receptor tyrosine kinase is mutated or amplified in ~6% of non-small cell lung cancer (NSCLC) and overexpressed in ~80% of all NSCLC cases. A theranostic agent that can both see and treat MET-altered NSCLC has never been described before in the literature. Here, we report a shark-derived single… |
Clinical Program phase | PRECLINICAL |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Single - cell cloning |
Overview Company | Celerion |
Overview Modality | CGT |
Overview Target | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Indication | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung Cancer.. The MET receptor tyrosine kinase is mutated or amplified in ~6% of non-small cell lung cancer (NSCLC) and overexpressed in ~80% of all NSCLC cases. A theranostic agent that can both see and treat MET-altered NSCLC has never been described before in the literature. Here, we report a shark-derived single… |
Clinical Safety signal | A MET-Targeted Variable New Antigen Receptor (VNAR) Theranostic for Non-Small Cell Lung Cancer.. The MET receptor tyrosine kinase is mutated or amplified in ~6% of non-small cell lung cancer (NSCLC) and overexpressed in ~80% of all NSCLC cases. A theranostic agent that can both see and treat MET-altered NSCLC has never been described before in the literature. Here, we report a shark-derived single… |
Clinical Program phase | PRECLINICAL |
추천 비교
추천 비교